Videos

Nitin Jain, MD, discusses a novel treatment approach for chronic lymphocytic leukemia, along with stem cell transplantation and other later-line therapies and treatment options for managing CLL.

Nitin Jain, MD, discusses the increasing use of various Bruton's tyrosine kinase inhibitors as front-line treatment options for patients with chronic lymphocytic leukemia.

Nitin Jain, MD, presents data on the efficacy of various chronic lymphocytic leukemia treatments, reviews current guidelines, discusses the increasing use of Bruton's tyrosine kinase inhibitors and the decreasing role of chemotherapy in his practice. He emphasizes the importance of considering patient factors and preferences in treatment decision-making.

Medical professionals discuss factors influencing the decision between observation and treatment, optimal diagnostic methods for chronic lymphocytic leukemia (CLL), and key markers to assess in patients with suspected CLL.

Administering neoadjuvant therapy to patients with colorectal cancer may help surgical oncologists attain a negative-margin resection.

An overview of frontline treatment options for patients with EGFR-mutated non–small cell lung cancer.

Expert perspectives on next-generation sequencing for patients with non–small cell lung cancer, highlighting challenges and the differences between RNA and DNA testing.

Christine Bestvina, MD, presents her treatment strategy for a 62-year-old female with NSCLC, bone and liver metastases, and an EGFR exon 20 insertion; the panel then assesses clinical data, including the MARIPOSA trial, to guide their treatment decisions.

Sandip Patel, MD, presents a case study of a 62-year-old female patient with a PD-L1 expression of 60%, an EGFR exon 20 insertion mutation, and liver lesions, followed by a panel discussion on diagnostic strategies to optimize patient care.

Increasing screening for younger individuals who are at risk of colorectal cancer may help mitigate the rising early incidence of this disease.

Laparoscopy may reduce the degree of pain or length of hospital stay compared with open surgery for patients with colorectal cancer.

Drs Costello and Pianko close their discussion by sharing advice for clinicians administering bispecifics to their patients with relapsed/refractory multiple myeloma.

Experts discuss key data on the outpatient management of teclistamab.

Matthew Pianko, MD, explains how patients with relapsed/refractory multiple myeloma are monitored for CRS and ICANS.

Caitlin Costello, MD, shares her thoughts on administering teclistamab to patients with relapsed/refractory multiple myeloma in an outpatient setting.

Key opinion leaders discuss how bispecifics are administered at their institutions.

Experts review how the treatment landscape for relapsed/refractory multiple myeloma shifted with the addition of bispecifics, and the currently approved bispecifics available.

Sam Klempner, MD, provides insight on HER2-targeted therapy for patients with upper GI cancer, and the Oncology Brothers recap the entire discussion.

Medical oncologists discuss the role for comprehensive next-generation sequencing (NGS) in upper GI cancers and the potential role for zolbetuximab.

Dr Klempner and the Oncology Brothers discuss the treatment paradigm for patients with metastatic upper GI cancers.

The Oncology Brothers and Sam Klempner, MD, offer comprehensive insights on treating residual disease in upper GI cancers following FLOT treatment.

Sam Klempner, MD, joins Rahul Gosain, MD, and Rohit Gosain, MD, to discuss treatment strategies for esophageal, GE junction, and gastric cancers.

The use of proton therapy may offer a more specific depth charge compared with conventional radiation, according to Timothy Chen, MD.

ZAP-X may provide submillimeter accuracy when administering radiation to patients with brain tumors.

The discussion on biomarker testing practices for patients with non–small cell lung cancer turns its focus to the metastatic setting.

A panel of medical oncologists introduce themselves and provide clinical insights on biomarker testing practices for patients with non–small cell lung cancer.

The expert panel provides closing remarks on exciting developments in the evolving treatment landscape in multiple myeloma.

Molecular profiling is a tool that can best determine first-line therapy options for patients with advanced RCC.

Clinicians are learning how to identify adverse effects relating to either immunotherapy or tyrosine kinase inhibitors for patients with advanced renal cell carcinoma.

Moshe Ornstein, MD, discusses the heterogeneous population that comprise patients with advanced renal cell carcinoma.